课题基金 / 基金详情

Development of Pre-Erythrocytic Malaria Vaccines and antibodies

Development of Pre-Erythrocytic Malaria Vaccines and antibodies
前红细胞疟疾疫苗和抗体的开发
批准号：
10930465
负责人：
ROBERT A SEDER
金额：
$105.64万
依托单位：
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/10930465
关键词：
AdjuvantAdultAffinityAnimal ModelAntibodiesAntigensAreaB-LymphocytesBloodCharacteristicsChildClinical TrialsDevelopmentDrug KineticsErythrocytesFormulationGoalsHumanImmunityImmunologic AdjuvantsIn VitroInfantInfectionKenyaKnock-in MouseMalaria VaccinesMaliMediatingModelingMonoclonal AntibodiesMusPhase II Clinical TrialsPlasmodium falciparumPlasmodium vivaxProteinsRoleSafetySporozoitesT-LymphocyteTestingVaccinesYeastscircumsporozoite proteinimmunogenicityimprovedin vivoin vivo Modelmalaria infectionneutralizing monoclonal antibodiespreventsafety assessmenttransmission blockingvaccine developmentvaccine-induced antibodies

项目摘要

项目成果

ROBERT A SEDER的其他基金

相似基金

相关文献

中文摘要
翻译
今年的主要发现如下。 1.评估L9LS的安全性和有效性是在马里和肯尼亚的婴儿，幼儿和成人中进行的几项2期临床试验。 2.证明亲和力和细胞溶解活性是预测抗PfCSP单克隆抗体体内保护作用的两个主要体外特征 3.证明Fc效应子功能在介导抗PfCSP单克隆抗体体内保护中的作用 4.开发多种模型以提高抗PfCSP单克隆抗体的效力。 5.启动了针对Pf的多阶段疫苗的开发。
英文摘要
The major discovery this year are as follows. 1. Assessed the safety and efficacy L9LS is several Phase 2 clinical trials in Mali and Kenya in infants, young children and adults. 2. Demonstrated that affinity and cytolytic activity are the two major in vitro characteristics that predict in vivo protection by a monoclonal antibody against PfCSP 3. Demonstrated the role of Fc effector function for mediating protection in vivo by monoclonal antibodies against PfCSP 4. Developed multiple models to improve the potency of monoclonal antibodies against PfCSP. 5. Initiated development of a multi-stage vaccine against Pf.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates.
DOI： 10.1016/j.vaccine.2010.08.098
发表时间： 2010-10-21
期刊： VACCINE
影响因子： 5.5
作者： [Tewari, Kavita, Flynn, Barbara J., Boscardin, Silvia B., Kastenmueller, Kathrin, Salazar, Andres M., Anderson, Charles A., Soundarapandian, Velmurugan, Ahumada, Adriana, Keler, Tibor, Hoffman, Stephen L., Nussenzweig, Michel C., Steinman, Ralph M., Seder, Robert A.]
通讯作者： Seder, Robert A.
VACCINE DEVELOPMENT FOR TUBERCULOSIS
  • 批准号：
    7958684
  • 项目类别：
  • 资助金额：
    $5.57万
  • 财政年份：
    2009
  • 负责人：
    ROBERT A SEDER
  • 依托单位：
    TULANE UNIVERSITY OF LOUISIANA
DNA VACCINATION FOR PREVENTION OF VIRAL, PARASITIC AND MYCOBACTERIAL INFECTION
Development Of A Vaccine For Leishmania Major Infection
Development Of A Vaccine For Leishmania Major Infection
海外基金